Synaptogenix stockholders authorize issuance of shares underlying convertible preferred stock and warrants

Proposal – Authorization of Issuance of Common Stock The Company’s stockholders voted to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of shares of Common Stock underlying shares of convertible preferred stock and warrants issued by the Company pursuant to the terms of that certain Securities Purchase Agreement, dated November 17, 2022, by and among the Company and the investors named therein, in an amount equal to or in excess of 20% of Common Stock outstanding before the issuance of such convertible preferred stock and warrants (including the amortization payments made to the holders of convertible preferred stock in the form of issuance of common stock and upon the operation of anti-dilution provisions contained in such convertible preferred stock and warrants), by the following votes: Shares Voted For Shares Voted Against Abstentions 2,077,004 791,292 55,679